Blockade of central delta-opioid receptors inhibits salt appetite in sodium-depleted rats  by Nascimento, A.I.R. et al.
B
s
A
a
b
c
a
A
R
R
A
A
K
S
D
A
S
1
t
i
c
t
e
t
d
t
i
c
d
C
f
h
0Peptides 55 (2014) 110–119
Contents lists available at ScienceDirect
Peptides
j ourna l ho me pa g e: www.elsev ier .com/ locate /pept ides
lockade  of  central  delta-opioid  receptors  inhibits  salt  appetite  in
odium-depleted  rats
.I.R.  Nascimentoa,c, H.S.  Ferreirab, D.R.  Cerqueirac, J.B.  Fregonezec,∗
Department of Biological Sciences, State University of Southwest Bahia, 45200-000 Jequié, Bahia, Brazil
Life Sciences Department, Bahia State University, 41195-001 Salvador, Bahia, Brazil
Department of Physiology, Health Sciences Institute, Federal University of Bahia, 40110-100 Salvador, Bahia, Brazil
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 11 November 2013
eceived in revised form 20 February 2014
ccepted 20 February 2014
vailable online 3 March 2014
eywords:
alt intake
elta-opioid receptors
ngiotensin II
odium-depletion
a  b  s  t  r  a  c  t
Various  studies  have  investigated  the  role of  central  opioid  peptides  in feeding  behavior;  however,  only
a few  have  addressed  the  participation  of  opioids  in the  control  of salt  appetite.  The  present  study  inves-
tigated  the  effect  of  intracerebroventricular  injections  of the  -opioid  antagonist,  naltrindole  (5, 10  and
20  nmol/rat)  and  the  agonist,  deltorphin  II (2.5,  5, 10 and  20  nmol/rat)  on  salt  intake.  Two  protocols  for
inducing  salt  intake  were  used:  sodium-depletion  and  the  central  injection  of angiotensin  II.  In addition,
the  effect  of  a central  -opioid  receptor  blockade  on locomotor  activity,  on  palatable  solution  intake  (0.1%
saccharin)  and  on  blood  pressure  was  also  studied.  The  blockade  of central  -opioid  receptors  inhibits  salt
intake in sodium-depleted  rats,  while  the pharmacological  stimulation  of  these  receptors  increases  salt
intake in sodium-replete  animals.  Furthermore,  the  blockade  of  central  -opioid  receptors  inhibits  salt
intake induced  by central  angiotensinergic  stimulation.  These  data  suggest  that  during  sodium-depletion
activation  of the  -opioid  receptors  regulates  salt  appetite  to correct  the  sodium  imbalance  and  it is  possi-
ble  that  an  interaction  between  opioidergic  and  angiotensinergic  brain  system  participates  in this  control.
Under  normonatremic  conditions,  -opioid  receptors  may  be necessary  to  modulate  sodium  intake,  a
response  that  could  be mediated  by  angiotensin  II.  The  decrease  in  salt  intake  following  central  -opioid
receptors  blockade  does  not  appear  to be  due  to  a general  inhibition  of  locomotor  activity,  changes  in
palatability  or  in  blood  pressure.
©  2014  Elsevier  Inc.  All  rights  reserved.. Introduction
The endogenous opioid system is widely distributed throughout
he brain and has been shown to be involved in multiple functions
ncluding antinociception, mood, feeding and drinking behavior,
ardiovascular control and endocrine regulation [8]. Opioid pep-
ides are classiﬁed into four well-deﬁned pharmacological families:
ndorphins, enkephalins, dynorphins and nociceptin/orphanin FQ
hat act through G-protein-coupled receptors referred to as mu,
elta, kappa and nociceptin/orphanin FQ receptor [8,68,69]. Of
hese opioid receptors, -opioid receptors are particularly interest-
ng as an alternative to -opioid drugs for the clinical treatment of
hronic pain [5,10,73]. In the near future, drugs targeted at -opioid
∗ Corresponding author at: Universidade Federal da Bahia, Instituto de Ciências
a Saúde, Departamento de Biorregulac¸ ão, Av. Reitor Miguel Calmon, s/n, Vale do
anela, 40110-100 Salvador, Bahia, Brazil. Tel.: +55 07188816353;
ax: +55 07132357518.
E-mail address: josmara@ufba.br (J.B. Fregoneze).
ttp://dx.doi.org/10.1016/j.peptides.2014.02.012
196-9781/© 2014 Elsevier Inc. All rights reserved.receptors may  also be used as therapeutic tools in addictive and
impulsive disorders, as well as in anxiety and depression [58].
Different studies have demonstrated the participation of the
brain opioid system in the regulation of feeding behavior through
a mechanism that may  involve modulation of the reward-related
responses and the palatability of different substances [9,42,44,66].
Indeed, morphine and opioid agonists induce a preference for fat
and sweet food/solutions [9,26]. Few studies have addressed the
role of opioid peptides in salt intake. The antagonist opioid, nalox-
one, administered both systemically and into the central nervous
system, reduces the intake of hypertonic, hypotonic and isotonic
saline solutions, which are preferred over water by ﬂuid-deprived
rats [15,25,27,28]. On the contrary, intracerebroventricular injec-
tions of selective -, - and -opioid agonists increase saline intake
in non-deprived rats [27,28]. Previous data from our laboratory
have shown that -opioid receptors may  regulate salt appetite,
since intracerebroventricular injections of nor-binaltorphimine
(Nor-BNI), a -opioid receptor antagonist, inhibit salt intake in
sodium-depleted rats [55]. In addition, -opioid receptors also
appear to be involved in the control of ingestive behavior related
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o palatable substances. Deltorphin II, a -opioid receptor agonist,
njected intracebroventricularly, has been shown to increase
ucrose solution intake [60], while the antagonist, naltrindole,
ad no effect on sucrose solution intake [3]. In a study using the
wo-bottle choice test approach (water and saline solution 0.6%
nd 1.7%) in ﬂuid-deprived rats, central administration of - and
-antagonists, but not -antagonists, decreases water intake.
n addition, all the antagonists used in that study were able to
lter saline solution intake [7]. On the other hand, salt intake in
odium-depleted rats is decreased by subcutaneous injection of
altrindole, a -opioid antagonist [45]. However, in that study, a
ingle dose of naltrindole was used and this was  the only approach
sed to study salt appetite. In order to clarify the role of -opioid
eceptors in the control of salt appetite, the present study was
esigned to investigate the effect of intracerebroventricular injec-
ions of different doses of a -opioid agonist and antagonist using
wo different approaches. These approaches have been largely
sed in the literature to study salt intake: (1) sodium deﬁciency
roduced by a single administration of the diuretic furosemide;
nd (2) intracerebroventricular injection of angiotensin II in rats
ith normal sodium balance. In addition, the effect of central
-opioid receptor blockade on locomotor activity, on palatable
olution intake (0.1% saccharin) and on blood pressure was also
nvestigated. The hypothesis is that central -opioid receptors par-
icipate in modulating salt intake during homeostatic challenges
nd may  be important for the correction of sodium imbalance.
. Methods
.1. Animals
The present study used adult male Wistar rats weighing
50–280 g. The animals were kept under controlled light (lights
n from 5 AM to 7 PM)  and temperature (22 ± 2 ◦C) conditions with
ree access to tap water and laboratory chow (Nuvital Nutrientes
tda., Curitiba, Brazil). Groups of rats used in one experimental set
ere not reused in any other part of the study. All experiments were
onducted between 7 AM and 11 AM.  The experimental protocols
ere performed in accordance with the regulations for the care of
aboratory animals and were approved by the Institution’s Animal
thics Committee (CEUA-ICS-UFBA # 024/2012).
.2. Surgical procedures
The animals were anesthetized with ketamine/xylazine
80/7 mg/kg i.p.) to allow the guide cannula (22-gauge) to be
nserted into the lateral ventricle (LV) in accordance with the fol-
owing coordinates: anteroposterior = 0.9 mm behind the bregma;
ateral = 1.5 mm;  vertical = 4.0 mm below the skull. The guide
annula was ﬁxed to the skull with metal screws and dental
ement and an obturator was provided to avoid obstruction. After
urgery, the animals were housed in individual cages and had
ree access to laboratory chow, distilled water and 1.5% saline
olution. The animals were handled every day to minimize the
tress of the experimental procedure. The position of the guide
annula in the LV and the intracerebroventricular injection site
ere conﬁrmed at the end of the experiment with the use of Evans
lue dye injected through the cannula. The brains were removed,
laced in formalin, and later frozen and cut into 40 m sections.
he slices were stained with cresyl violet and analyzed using light
icroscopy. Only data from the animals in which the tip of the
annula was restricted to the cerebroventricular space and the
vans Blue dye could not be seen in the brain tissue surrounding
he ventricle were included in the study.des 55 (2014) 110–119 111
2.3. Drugs and microinjections
The drugs used were naltrindole (NTI), an opioid antagonist
selective to -opioid receptors [57]; deltorphin II (Delt-II), an opi-
oid agonist with high selectivity and afﬁnity to -opioid receptors
[20,38]; and angiotensin II (AII). Both NTI and Delt-II were acquired
from Tocris Bioscience, Ellisville, MO,  USA, while AII was purchased
from Sigma Chemical, Co., St. Louis, MO,  USA. The doses of the drugs
used in this study were compatible with previous reports: 5, 10 and
20 nmol/rat of naltrindole [7], while the doses of deltorphin II were
2.5, 5, 10 and 20 nmol/rat [72] and 10 ng/rat of AII [21]. Central
injections were given using a Hamilton microsyringe connected to
a 30-gauge injector through polyethylene tubing (PE10). A total vol-
ume of 2 l was slowly injected (60 s). Furosemide, a loop diuretic,
was purchased from Sanoﬁ-Aventis Ltd., São Paulo, Brazil.
2.4. Sodium depletion (Experiments 1, 2 and 3)
Sodium depletion was achieved by means of a subcutaneous
injection of furosemide (20 mg/kg). After the injections, the rats
had free access to distilled water, while the standard rat chow
was replaced by a low sodium diet (0.001% Na+ and 0.33% K+). In
Experiment 1, the participation of central -opioid receptors in the
regulation of salt appetite was  tested in different groups of sodium-
depleted animals receiving LV injections of NTI at different doses
(5, 10 and 20 nmol) or saline. In Experiment 2, sodium-depleted ani-
mals received an LV injection of 20 nmol of NTI plus Delt-II at the
doses of 2.5, 5, 10 and 20 nmol, or saline, to conﬁrm the speciﬁcity
of NTI. In both experimental sets, sodium-depleted control animals
received LV injections of isotonic saline solution. In Experiment 3,
the aim was to test the effect of pharmacological stimulation of the
central -opioid receptors on salt appetite. Sodium depleted rats
and normonatremic animals (not submitted to sodium-depletion)
received an LV injection of 20 nmol of Delt-II or saline. In all three
experimental sets, bottles containing hypertonic saline solution
(1.5%) and distilled water were reintroduced into the cages 15 min
after the central injections. Fluid intake measurement began 5 min
later and continued for the next 120 min. To conﬁrm the efﬁcacy
of sodium depletion, an additional control group was included. In
this group, the animals received subcutaneous injections of isotonic
saline solution instead of furosemide and LV injections of isotonic
saline solution. As expected, salt intake was signiﬁcantly higher
in the sodium depleted (furosemide treated) rats compared to the
normonatremic (saline treated) rats, as shown in Table 1.
2.5. Central angiotensinergic stimulation (Experiment 4)
In this experimental group, the objective was  to study the role
of -opioid receptors in the salt appetite induced by the pharmaco-
logical stimulation of central angiotensinergic pathways. Different
groups of normonatremic rats received LV injections of NTI at
different doses (5, 10 and 20 nmol) 15 min  before receiving AII
(10 ng/rat). Bottles containing 1.5% saline solution and distilled
water were replenished and made available immediately after the
LV injections of AII. As in the previous experimental sets, the mea-
surement of ﬂuid intake began 5 min  after reintroduction of the
bottles into the cages and continued for the next 120 min.
2.6. Open ﬁeld test (Experiment 5A)
The aim of this experimental set was  to exclude the possi-
bility that the -opioid receptor antagonist could have induced
a locomotor alteration that would explain the inhibition of salt
intake observed in experiments 1 and 3. Different groups of
sodium-depleted rats receiving LV injections of NTI (20 nmol) or
saline solution were submitted to an open ﬁeld test. In this test, the
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Table 1
Effect of sodium depletion induced by furosemide treatment and low sodium diet on salt and water intake.
Fluid intake Water intake (ml/100 g b.w.) Salt intake (ml/100 g b.w.)
Treatment NN (n = 12) SD (n = 11) NN (n = 12) SD (n = 11)
Time (min)
5  0.00 ± 0.00 0.07 ± 0.07 0.06 ± 0.01 0.80 ± 0.20*
10 0.10 ± 0.01 0.26 ± 0.24 0.06 ± 0.01 1.97 ± 0.45*
15 0.10 ± 0.01 0.34 ± 0.32 0.06 ± 0.01 3.19 ± 0.45*
30 0.10 ± 0.01 0.39 ± 0.32 0.06 ± 0.01 4.99 ± 0.33*
45 0.10 ± 0.01 0.41 ± 0.34 0.06 ± 0.01 5.60 ± 0.45*
60 0.20 ± 0.14 0.41 ± 0.34 0.06 ± 0.01 6.53 ± 0.43*
90 0.33 ± 0.18 0.81 ± 0.45 0.06 ± 0.01 6.95 ± 0.27*
120 0.78 ± 0.45 2.08 ± 0.73* 0.06 ± 0.01 7.25 ± 0.29*
Fluid intake Water intake (ml/100 g b.w.) Salt intake (ml/100 g b.w.)
Mixed model ANOVA F(DFn,DFd) p F(DFn,DFd) p
Interaction
(time × treatment)
F(7,154) = 4.117 =0.0004 F(7,154) = 50.14 <0.0001
Time  F(7,154) = 7.375 <0.0001 F(7,154) = 57.07 <0.0001
Treatment F(1,22) = 4.135 =0.0542 F(1,22) = 238.2 <0.0001
Data presents as mean ± SEM. The data were analyzed by a mixed-model analysis of variance (ANOVA) with one repeated measures factor (eight levels of time) and one
g atrem
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* Signiﬁcant difference when the ﬂuid intake by SD rats is compared to NN rats (
nimals were placed in a circular acrylic box (60 cm in diameter
nd 60 cm high) with an open top 30 min  after an injection of NTI
r saline solution into the LV. The ﬂoor was divided into eight areas
f equal size with a circle at the center (42.43 cm). Hand-operated
ounters and stopwatches were used to score locomotion over a
0-min period by measuring the number of areas into which the
ats entered with all four paws. The behavioral experiments took
lace in a sound-attenuated, temperature-controlled (24 ± 1 ◦C)
oom between 7 AM and 11 AM.  A white-noise generator provided
onstant background noise and the apparatus was cleaned with 70%
thanol and dried before each session to minimize olfactory cues.
.7. Dessert test (Experiment 5B)
The dessert test, a well-established model of hedonic behavior
n rats, was performed to exclude the possibility of a non-speciﬁc,
eneral inhibition of the central nervous system induced by the -
pioid receptor antagonist observed in experiments 1 and 3 [19,33].
n this experiment, after LV cannulation, the animals were kept
n the usual individual cages during the training period with free
ccess only to tap water and were transferred to a different cage
the “test cage”) for 2 h each day for seven consecutive days. In
he test cage, the animals had access to two bottles: one contain-
ng water and the other containing a 0.1% saccharin solution. After
his training period, the animals were divided into two  groups
nd deprived of ﬂuid for 24 h. Afterwards, the animals received
V injections of NTI (20 nmol) or saline (controls) 15 min  before
eing transferred to the test cage. Intake of the water and the 0.1%
accharin solution was recorded over a 120-min period.
.8. Blood pressure recording (Experiment 6)
In this experimental group, the objective was to exclude the pos-
ibility that the inhibitory effect of the -opioid receptor antagonist
n salt appetite could be due to changes in blood pressure. One day
efore the experimental sessions, a catheter (PE50) ﬁlled with hep-
rin solution (1000 U/ml) was inserted into the left carotid artery
nder ketamine/xylazine (80/7 mg/kg i.p.) anesthesia, and exteri-
rized at the nape of the animal’s neck to permit blood pressure
ecording. At the experimental session, the carotid catheter was
onnected to a pressure transducer whose signal was  ampliﬁedic.
roni’s post-test).
and digitally recorded by an analog-to-digital interface (AqDados,
version 5, Lynx Tecnologia Eletrônica Ltda, São Paulo, Brazil) and
recorded (1 kHz) on a microcomputer for posterior analysis. Dis-
tinct groups of sodium-depleted animals received an LV injection
of NTI (20 nmol) or saline solution (controls) 20 min  after baseline
blood pressure was recorded. In each of these groups, blood pres-
sure continued to be recorded for the next 120 min  after NTI or
saline solution was injected. The experimental protocol used in this
case was  identical to that used to study salt intake in the previous
groups. Mean arterial pressure (MAP) was calculated from sys-
tolic and diastolic pressure measurements using the AcqKnowledge
software program, version 3.5.7, developed by Biopac Systems, Inc.,
California, USA. The MAP  values at the end of the stabilization
period were used as references to calculate the delta values that
are presented here.
2.9. Statistical analysis
The data are presented as means ± standard error of the mean
(SEM). Statistical analyses were performed using the GraphPad
Prism software (GPAD, version 6.03, San Diego, USA). The amount
of water and sodium chloride solution consumed was analyzed
separately using a mixed-model analysis of variance (ANOVA)
with time as the within-subjects repeated measure (eight levels of
time) and drug treatment as the between-subjects variables (not
repeated). The Bonferroni post hoc test was  used to compare the
effects of the drugs during each measurement period. The data
from the open ﬁeld and dessert tests were analyzed using Stu-
dent’s t-test. The delta values of MAP  were analyzed using two-way
repeated-measures ANOVA followed by the Bonferroni post hoc
test. Differences between the groups were considered statistically
signiﬁcant when p < 0.05.
3. Results
3.1. Experiment 1 – effect of central ı-opioid receptor blockade
on salt appetite in sodium-depleted ratsCumulative salt intake in sodium-depleted rats after LV injec-
tions of NTI at the doses of 5 (n = 10), 10 (n = 10) and 20 nmol
(n = 10) is shown in Fig. 1 (Panel A). As expected, salt intake was
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Table  2
Statistic summary of mixed model ANOVA.
Experiments Interaction (time × drug) Time Drug
F(DFn,DFd) p F(DFn,DFd) p F(DFn,DFd) p
Experiment 1
Salt intake F(21,259) = 7.323 <0.0001 F(7,259) = 116.0 <0.0001 F(3,37) = 18.73 <0.0001
Water intake F(21,259) = 1.141 =0.3057 F(7,259) = 12.12 <0.0001 F(3,37) = 1.509 =0.2282
Experiment 2
Salt intake F(35,413) = 5.863 <0.0001 F(7,413) = 137.0 <0.0001 F(5,59) = 7.983 <0.0001
Water intake F(35,413) = 0.578 =0.9754 F(7,413) = 15.06 <0.0001 F(5,59) = 0.099 =0.9918
Experiment 3
SD: salt intake F(7,126) = 0.822 =0.5707 F(7,126) = 109.9 <0.0001 F(1,18) = 0.448 =0.5115
SD:  water intake F(7,126) = 0.653 =0.7110 F(7,126) = 8.768 <0.0001 F(1,18) = 0.635 =0.4357
NN:  salt intake F(7,126) = 8.281 <0.0001 F(7,126) = 10.83 <0.0001 F(1,18) = 14.58 =0.0013
NN:  water intake F(7,126) = 4.044 =0.0005 F(7,126) = 6.209 <0.0001 F(1,18) = 4.027 =0.0601
Experiment 4
Salt intake F(21,203) = 3.146 <0.0001 F(7,203) = 89.87 <0.0001 F(3,29) = 21.19 <0.0001
Water intake F(21,203) = 1.214 <0.0001 F(7,203) = 123.2 <0.0001 F(3,29) = 2.252 =0.1034
The amount of water and sodium chloride solution consumed was  analyzed separetely using a mixed-model analysis of variance (ANOVA) with one repeated measures factor
(eight  levels of time) and one group factor (drugs) not repeated. The post hoc test used to compare the effect of the drugs at each measurement time period was Bonferroni
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snd  is shown in Fig. 1-3. SD = sodium depleted; NN = normonatremic.
igh in the sodium-depleted rats receiving LV injections of isotonic
aline (n = 11). The LV injection of NTI induced a dose-dependent
nhibition of salt intake in sodium-depleted rats. NTI injections at
he doses of 10 and 20 nmol promoted an inhibitory effect that
egan after the initial 15 min  of the measurement period and lasted
ntil the end of the experiment. At the lowest dose (5 nmol), the
nhibitory effect was signiﬁcant only at 120 min of the measure-
ent period. Furthermore, in the sodium-depleted rats receiving
V injections of 5 nmol of NTI, salt intake was signiﬁcantly dif-
erent from that of the animals treated with NTI at the doses of
0 and 20 nmol after the ﬁrst 30 min  of the measurement period.
ig. 1 (Panel B) shows the effect of LV injections of NTI at the doses
f 5, 10 and 20 nmol on water intake in sodium-depleted rats. As
xpected, water intake was negligible in sodium-depleted rats and
emained unaltered by any of the treatments. The results of the
ixed model ANOVA applied to the data on salt and water intake
n this experimental set are shown in Table 2.
.2. Experiment 2 – effect of the ı-opioid receptor agonist,
eltorphin II, on the inhibitory action of naltrindole on salt
ppetite in sodium-depleted animals
The effect of different doses of Delt-II (2.5, 5, 10 and 20 nmol)
n the NTI-induced inhibition of salt intake (20 nmol, n = 12) in
odium-depleted rats is shown in Fig. 2 (Panel A). As in the pre-
ious experiment, at the dose of 20 nmol NTI exerted a signiﬁcant
nhibitory effect on salt intake throughout the entire measurement
eriod compared to sodium-depleted rats receiving LV isotonic
aline injections. At the lowest dose, 2.5 nmol (n = 12), Delt-II failed
o signiﬁcantly alter the inhibitory effect of NTI on salt intake. How-
ver, at the doses of 5 (n = 13) and 10 nmol (n = 6), the inhibition of
alt appetite induced by NTI began to be attenuated at 45 min  of the
easurement period, and at the dose of 20 nmol (n = 12) this effect
as already seen at 30 min  of the measurement period. Fig. 2 (Panel
) shows the effect of LV injections of the -opioid receptor antag-
nist (NTI 20 nmol) plus the agonist (Delt-II 2.5, 5, 10 and 20 nmol)
n water intake in sodium-depleted rats. As expected, water intake
as very low in sodium-depleted rats and remained unaltered by
ny of the treatments. The results of the mixed model ANOVA
pplied to the data on salt and water intake in this experimental
et are shown in Table 2.3.3. Experiment 3 – effect of pharmacological stimulation of the
central ı-opioid receptors on salt appetite
The effect of LV injections of Delt-II at the dose of 20 nmol
or saline on salt intake in sodium-depleted animals and in nor-
monatremic rats (not submitted to sodium-depletion) is shown
in Fig. 3. In sodium-depleted animals, Delt-II had no effect on the
high salt intake when compared to saline-treated, sodium-depleted
rats (Panel A). Furthermore, water intake remained unchanged
in sodium-depleted rats treated with Delt-II (Panel B). On the
other hand, in normonatremic rats, Delt-II (20 nmol) signiﬁcantly
increased salt intake compared to the controls, saline-treated nor-
monatremic rats, after the ﬁrst 60 min  of the measurement period
(Panel C). In addition, LV injections of Delt-II (20 nmol) increased
the water intake in normonatremic rats after 90 min  of the mea-
surement period (Panel D). The results of the mixed model ANOVA
applied to the data on salt and water intake in this experimental
set are shown in Table 2.
3.4. Experiment 4 – effect of ı-opioid receptor antagonist,
naltrindole, on salt and water intake induced by central
angiotensinergic stimulation
The effect of LV injections of NTI at the doses of 5 (NTI-5 + AII;
n = 10), 10 (NTI-10 + AII; n = 7) and 20 nmol (NTI-20 + AII; n = 8) on
cumulative salt intake induced by 10 ng of AII is shown in Fig. 4,
Panel A. As expected, salt intake was  signiﬁcantly higher in the
saline + AII group. LV injections of NTI at the doses of 10 and 20 nmol
(NTI-10 + AII and NTI-20 + AII) inhibited the salt intake induced by
AII after the initial 15 min  of the measurement period and lasted
until the end of the experiment. The salt intake observed in the
NTI-5 + AII group was similar to that of the saline + AII group. Fig. 4,
Panel B, shows the effect of LV injections of NTI at the doses of 5,
10 and 20 nmol on cumulative water intake induced by 10 ng of
AII. As expected, water intake was  high in the saline + AII group.
In the groups treated with LV injections of NTI at any of the
doses used, water intake was  similar to that of the saline + AII
group. The results of the mixed model ANOVA applied to the data
on salt and water intake in this experimental set are shown in
Table 2.
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Fig. 1. Cumulative salt (Panels A) and water intake (Panel B) following lateral ven-
tricle injections of saline or naltrindole (NTI) at different doses (5, 10 and 20 nmol) in
sodium-depleted rats. Data are presented as means ± SEM. The letter “a” indicates
a  statistically signiﬁcant difference (mixed-model ANOVA followed by Bonferroni’s
test; p < 0.05) when compared to animals receiving saline; the letter “b” indicates a
statistically signiﬁcant difference when compared to sodium-depleted rats receiv-
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Fig. 2. Cumulative salt (Panels A) and water intake (Panel B) in sodium-depleted ani-
mals pretreated with lateral ventricle injections of naltrindole (NTI 20 nmol) before
receiving central administration of deltorphin II (Delt 2.5, 5, 10 and 20 nmol). Data
are  presented as means ± SEM. The following groups are presented: saline + saline,
NTI + saline, NTI + Delt-II 2.5 nmol, NTI + Delt-II 5 nmol, NTI + Delt-II 10 nmol and
NTI + Delt-II 20 nmol. The letter “a” indicates a statistically signiﬁcant difference
(mixed-model ANOVA followed by Bonferroni’s test; p < 0.05) when the distinctng  5 nmol of NTI; the letter “c” indicates a statistically signiﬁcant difference when
ompared to sodium-depleted rats receiving 10 nmol of NTI. Each group has been
btained from naïve animals.
.5. Experiment 5 – effect of the ı-opioid receptor antagonist on
ocomotor activity and hedonic behavior in rats
Fig. 5 shows the results of the Open Field Test and Dessert Test.
n the open ﬁeld test, central blockade of -opioid receptors failed
o alter locomotor activity in sodium-depleted rats. Locomotor
ehavior was similar in sodium-depleted animals receiving LV
njections of NTI (20 nmol; n = 11) or saline solution (n = 11). In the
essert test, the hedonic behavior represented by a preference for
 palatable solution was conﬁrmed by the higher saccharin (0.1%)
ntake compared to water intake in the saline-treated control
nimals. LV injections of NTI (20 nmol; n = 7) failed to alter this
edonic preference.
.6. Experiment 6 – effect of the ı-opioid receptor antagonist on
lood pressure in sodium-depleted ratsFig. 6 shows the effects of NTI (20 nmol, n = 8) on blood
ressure in rats submitted to sodium depletion using the same
xperimental protocol used to study salt intake. Baseline bloodgroups of animals are compared to controls (saline + saline); the letter “b” indicates
a  statistically signiﬁcant difference when compared to the group NTI + saline. Each
group has been obtained from naïve animals.
pressure was  94.4 ± 1.6 mmHg  in the group treated with NTI
and 100.4 ± 3.7 mmHg  in the saline-treated control group. Cen-
tral administration of NTI failed to modify blood pressure in
sodium-depleted animals compared to sodium-depleted con-
trols (saline-treated, n = 5) throughout the entire experimental
period. Two-way ANOVA analysis shows that LV injections of NTI
induced no signiﬁcant treatment (F1,132 = 0.15; p = 0.7065), time
(F12,132 = 1.25; p = 0.2557) or interaction (F12,132 = 0.73; p = 0.7192)
changes in blood pressure compared to the control group.4. Discussion
The aim of the present study was to investigate the role of
central -opioid receptors on sodium appetite induced by sodium
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Fig. 3. Cumulative ﬂuid intake following lateral ventricle injections of saline or deltorphin II (20 nmol) in sodium-depleted rats (Panels A: salt intake and Panel B: water
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antake) and in normonatremic rats, not submitted to sodium-depletion (Panels C: s
ndicates a statistically signiﬁcant difference (mixed-model ANOVA followed by Bon
btained from naïve animals.
epletion and by central angiotensinergic stimulation. Preference
or hypertonic (1.5%) saline over distilled water was  evaluated in
oth sodium-depleted and sodium-replete rats. The main ﬁndings
how that blockade of central -opioid receptors inhibits salt intake
n sodium-depleted rats, while the pharmacological stimulation of
hese receptors increases salt intake in sodium-replete animals.
urthermore, the blockade of central -opioid receptors inhibited
he salt intake induced by central angiotensinergic stimulation. It
as also found that the blockade of -opioid receptors did not
hange the locomotor activity of the animals, their blood pressure
r their preference for saccharin in the dessert test.
Some conditions that induce thirst also trigger sodium appetite
1,17,21,34]. A complex interplay between stimulatory drives
uch as mineralocorticoid and angiotensin II [23,62] and negative
nputs such as the oxytocinergic [6,64] and serotonergic inputs
11,12,48,49,52] is important in the control of salt appetite. In a pre-
ious study, our group showed that central kappa-opioid receptor
lockade inhibited salt intake in sodium-depleted rats, but failed to
lter salt intake in normonatremic animals [55]. These data suggestake and Panel D: water intake). Data are presented as means ± SEM. The letter “a”
ni’s test; p < 0.05) when compared to animals receiving saline. Each group has been
that k-opioid receptors may  be activated during sodium deple-
tion, increasing salt intake. The present study shows that central
-opioid receptors may also participate in controlling salt intake.
In addition, the present data indicate that the interaction between
angiotensinergic and opiadergic systems in the brain is important
for the control of sodium appetite in rats.
The opioidergic pathways and opioid receptors are widely dis-
tributed throughout the brain [16,42,51,71]. The endorphin family
is produced mainly in the arcuate nucleus of the hypothalamus,
pituitary and nucleus of the solitary tract. The neuronal system
producing enkephalin and dynorphin is more broadly distributed
in the brain and it has been reported that in some areas both opioid
peptides are present in the same neuron. The endorphin peptides
bind mainly to -opioid receptors, while enkephalin binds to -
opioid receptors and dynorphin peptides bind to k-opioid receptors
[16,71].
In the present study, blockade of central -opioid receptors
by LV injection of the antagonist naltrindole induced a dose-
dependent inhibition of salt intake in sodium-depleted rats. This
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Fig. 4. Cumulative salt (Panel A) and water intake (Panel B) in animals pretreated
with lateral ventricle injections of saline or naltrindole (NTI) at different doses
(5,  10 and 20 nmol), prior to receiving central administration of angiotensin II
(AII10 ng). The following groups are presented: saline + AII 10 ng, NTI 5 nmol + AII,
NTI  10 nmol + AII, and NTI 20 nmol + AII. Data are presented as means ± SEM. The let-
ter “a” indicates a statistically signiﬁcant difference (mixed-model ANOVA followed
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sy  Bonferroni’s test; p < 0.05) when compared to the group saline + AII; the letter “b”
ndicates a statistically signiﬁcant difference when the groups NTI 5 nmol + AII. Each
roup has been obtained from naïve animals.
nhibition was reverted by pre-treatment with deltorphin II, a -
pioid receptor agonist, at different doses. Both the agonist and
he antagonist used in the present study have been shown to
e selective for -opioid receptors [20,38,57]. Few studies in the
iterature have evaluated the role of -opioid receptors on salt
ntake regulation. Intracerebroventricular injection of naltrindole
as been shown to have no effect on hypotonic (0.6%) or hypertonic
1.7%) saline intake in the two-bottle (water/saline) preference test,
lthough the dose of naltrindole used in the reported experiments
as higher (42 nmol/rat) than the dose used in the present study
5–20 nmol/rat) [7]. Furthermore, in that study, Bodnar’s group
sed 24-h ﬂuid deprivation instead of sodium-depletion to induce
alt intake. Sodium-depletion has been shown to be a stronger
timulus for salt appetite than 24-h ﬂuid deprivation [47,53]. In
tudies using a sodium-depletion procedure, both systemic anddes 55 (2014) 110–119
intracerebral injections of naltrindole have been reported to blunt
salt appetite [45,46]. However, in those studies, only one dose of
naltrindole was  used, whereas in the present study the use of dif-
ferent doses revealed a dose-dependent inhibition of salt appetite
in sodium-depleted rats. These data suggest that during sodium-
depletion an increase may  occur in endogenous opioid peptides
that, by acting on -opioid receptors, regulate salt appetite to cor-
rect the sodium imbalance. Indeed, an increase has been reported
in the levels of enkephalin mRNA at the shell of the nucleus accum-
bens in sodium-depleted rats with access to hypertonic saline [45].
Those authors suggested that central enkephalin participates in the
reward mechanism controlling salt appetite and the data from the
present study corroborate this hypothesis.
One of the mechanisms that may  be involved in the regula-
tion of salt appetite in animals submitted to sodium-depletion is
the renin–angiotensin system (RAS) [21,34]. Central injections of
angiotensin II promote robust water and sodium intake in nor-
mohydrated and normonatremic animals, which can be inhibited
by losartan, an AT1 angiotensin receptor antagonist. Inhibition of
the angiotensin-converting enzyme (ACE), both in the periphery
and in the central nervous system, has been shown to reduce or
completely inhibit salt appetite induced by sodium-depletion [34].
The aldosterone and AII produced in the peripheral system and the
brain RAS may  have a synergic action stimulating salt intake to a
greater degree than the action of either hormone alone [24].
The circumventricular organs such as the subfornical organ
(SFO), organum vasculosum of the lamina terminalis (OVLT)
and area postrema (AP) are important in sensory sites for
humoral signals in blood or interstitial ﬂuid [35,56,70]. Indeed,
sodium-depletion induced by furosemide injections increases
Fos expression in the SFO, OVLT, median preoptic area, central
amygdala (CeA), accumbens nucleus (NAc), bed nucleus of stria
terminalis (BST), paraventricular, supraoptic, suprachiasmatic and
ventromedial hypothalamic nuclei, nucleus of the solitary tract
and lateral parabrachial nucleus [18,30,54,59,65,67]. Additionally,
co-localization of AT1 receptors and Fos protein in the neuronal
population of SFO and OVLT has been shown during sodium-
depletion [29]. The increase in neuronal activation induced by
sodium-depletion in some brain areas, including the NAc, CeA
and BST, is also associated with an increase in the mRNA for
enkephalin [30]. The stimulation of these structures during sodium-
depletion may  initiate activation of a brain network controlling
sodium appetite, and the brain enkephalinergic system may  play
an important role in this control.
There is some anatomic evidence of an interaction between
angiotensinergic and enkephalinergic systems in the brain. In a
double immunostaining study using light and electronic micro-
scopic analysis, reciprocal synaptic connections were detected
between angiotensin II-containing neurons and enkephalinergic
neurons in the area postrema [31]. Furthermore, it has been shown
that ACE may  participate in the metabolic inactivation of the
neuropeptides terminating the enkephalin action [37,50,63]. It is
interesting to note that in sodium-depleted rats there is some
degree of overlap of the brain areas in which there is up-regulation
of AT1 receptors mRNA [14,29] and brain areas in which there is an
increase in enkephalinergic mRNA [30]. This provides the necessary
anatomical background to support the present ﬁndings.
The present study showed that the blockade of -opioid recep-
tors inhibits salt intake in sodium-depleted rats. Since the brain RAS
may  mediate salt appetite in sodium-depleted rats, we also decided
to investigate the effect of a -opioid receptor antagonist on the salt
intake directly induced by a central injection of AII. It was found that
LV injections of naltrindole inhibit the salt intake induced by central
angiotensinergic stimulation in a dose-dependent manner. On the
other hand, the water intake induced by angiotensin II remained
unchanged by central injections of naltrindole. This ﬁnding shows
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Fig. 5. The number of areas entered during 15 min  in the Open Field Test carried out in rats receiving lateral ventricle injections of naltrindole (NTI 20 nmol) or saline. Data
are  expressed as means ± SEM. There was no statically signiﬁcant difference (t-test; p < 0.05) between the group of animals receiving NTI and the saline-treated animals. In
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he  treatment received by each group and the number of animals used is indicate
ifference (t-test; p < 0.05) when the group of animals receiving NTI was compared
hat in a two-bottle choice test, blockade of the -opioid receptors
peciﬁcally inhibits salt preference when the animals are able to
hoose between water and hypertonic saline, conﬁrming the effect
f -opioid receptors on salt preference.
The effect of -opioid receptors on water intake induced by
ngiotensin II may  depend on the experimental protocol used, since
entral injection of 40 nmol of naltrindole inhibits water intake
nduced by angiotensin when water is the only ﬂuid available [60].
n the contrary, stimulation of -opioid receptors by deltorphin
I increases water intake in normohydrated animals, again, when
ater is the only ﬂuid available. Furthermore, central injection of
eltorphin II increases the water intake induced by a very low dose
f angiotensin II (0.02 ng/10 l), but does not change the water
ntake induced by angiotensin II at a higher dose (2 ng/10 l) [72].
Pharmacological stimulation of the central -opioid receptors in
ormonatremic rats, a “salt need-free” condition, induces animals
ig. 6. Changes in mean blood pressure in sodium-depleted rats after injections of
altrindole (NTI 20 nmol or saline into the lateral ventricle. The injections were given
t  0 min and the bottles containing water and saline solution (1.5%) were imme-
iately accessible. Data are presented as means ± SEM. There was  no statistically
igniﬁcant difference between the groups (two-way ANOVA; p < 0.05).was recorded during 2 h after lateral ventricle injections of NTI (20 nmol) or saline.
he graph. Data are expressed as means ± SEM. There was no statically signiﬁcant
ine-treated group.
to drink a salt solution that is usually aversive. This fact suggests
that central -opioid receptors exert a facilitator effect on salt
intake behavior. On the other hand, during a “salt hunger” condition
(sodium-depletion) an increase may  take place in the activation
of central -opioid receptors that may  change perception of the
quality of the salt solution from aversive to palatable, driving ani-
mals to consume a large amount of salt until the sodium deﬁcit
is replenished. This response reﬂects sodium appetite and not a
hedonic ingestive behavior associated with a tasty salty solution. In
a “salt hunger” condition, pharmacological stimulation of -opioid
receptors failed to promote a further increase in salt intake. In both
“salt need-free” and “salt hunger” conditions, the animals drank a
very small volume of water and the blockade or the stimulation of
central -opioid receptors had no effect on water intake.
The role of the central opioidergic system in the control of feed-
ing behavior has been shown by several studies, while only a few
studies have investigated the participation of central opioid pep-
tides in the regulation of water intake and sodium appetite [8,9].
Both systemic and intracerebral injections of morphine and the
selective opioid receptor agonists increase food intake. In addi-
tion, opioid peptides appear to induce a preference for sweet and
fatty solutions [8,9]. Indeed intracerebral administration of mor-
phine and opioid peptide receptor agonists increase fat and sugar
intake [9,26]. Ingestive behavior may  be regulated by reward mech-
anisms involving the hedonic aspects of food and/or ﬂuid intake and
the homeostatic nature of the macro and micronutrients [2,4,26].
Substantial ﬁndings indicate that central opioid system controls
feeding behavior through a mechanism which involves the reward
and the palatability aspects of food intake [2,26,32,36,42]. In the
present study, the “dessert test”, a test used to evaluate the hedonic
aspect of ingestive behavior [19,33], shows that intake of a palat-
able saccharin solution is unaffected by LV injections of naltrindole.
These data suggest that the changes in salt intake promoted by
central -opioid receptors in both normonatremic (salt need-free
condition) and sodium-depleted (salt-hunger condition) rats are
unrelated to a general change in the palatability mechanisms reg-
ulating ingestive behavior.Central injections of opioid receptor antagonists have been
shown to decrease ambulatory and stereotyped activity [43]. These
effects could inﬂuence ingestive behavior. However, in the present
study, no change occurred in locomotor activity in the “open ﬁeld”
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est in sodium-depleted rats receiving central injections of nal-
rindole.
Central opioid peptides may  participate in the cardiovascu-
ar regulation [8,66], and both hypotensive and hypertensive
esponses have been observed after pharmacological manipula-
ion of central opioid pathways [39–41]. Changes in blood pressure
ay  affect salt intake; however, a hypertension-induced decrease
n salt intake can be excluded as the cause of the inhibitory ingestive
ehaviors observed in the present study, since intracerebroventric-
lar injections of naltrindole in sodium-depleted rats did not alter
lood pressure. Similar results were observed after both systemic
61] and central injections of naltrindole [13,22].
The data obtained in the present study conﬁrmed our hypothe-
is that central -opioid receptors participate in the modulation
f salt intake during homeostatic challenges. It is possible that
uring sodium-depletion, activation of the -opioid receptors reg-
lates salt appetite in order to correct the sodium imbalance, while
nder normonatremic conditions, -opioid receptors may  be nec-
ssary to maintain the normal sodium intake. Since in the present
tudy it was observed that blockade of -opioid receptors inhibits
alt intake induced by angiotensin II, it is possible to conclude
hat an interaction between opioidergic and angiotensinergic brain
ystem participates in the control of salt appetite. The decrease
n salt intake following central -opioid receptors blockade does
ot appear to be due to a general inhibition of locomotor activity,
hanges in palatability or in blood pressure. Given that the circum-
entricular structures have the ability to detect variations in plasma
ngiotensin II levels, they may  be important as a link between
hanges in peripheral hydroelectrolyte status and the brain opi-
idergic system in the control of body ﬂuid homeostasis. However,
ther studies are need to clarify the brain areas participating in the
ontrol of salt appetite modulated by -opioid receptors.
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